UNSPSC 51171844: Nabilone

This classification denotes an antiemetic agent with the molecular formula C24H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N4O9L084N, chemically known as 9h-dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, trans-(.+/-.)- but generally known as nabilone, which bears US NIH Compound Identifier 39860. European Medicines Agency schedules Nabilone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09104MIG.

UNSPSC 51171844 Nabilone, a Commodity code, nominally designates a single pharmaceutical product but recent state and local activity shows this code applied inconsistently across specimen collection, drug testing, and broader pharmaceutical distribution procurement. The solicitations tag work spanning offender drug-testing services, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceutical supply—only tangentially related to nabilone itself. State and local buyers using this code are acquiring comprehensive drug-testing infrastructure including laboratory certification, specimen collection staffing, confirmatory testing via LC/MS/MS or GC/MS, and alternative testing modalities (oral fluid, hair), as well as generic pharmaceutical products distributed through wholesalers with supply-chain security and manufacturing-practice compliance. Issuing bodies include county-level correction and supervision departments, state health and human services agencies, and multi-state cooperative purchasing alliances.

Geographic activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department solicited offender specimen collection and drug testing services via RFP 2026-327 due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, with three optional one-year renewals; the scope covers two collection sites in Plano and McKinney with approximately 25,031 annual tests across five- and six-panel screens and ancillary testing, evaluated on vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points). Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside existing pharmacy benefit manager and wholesaler arrangements. Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers, with a contract term of two years for new vendors and pricing evaluation weighted 75 percent on competitiveness.